Search the Newsreel

Proto Labs Inc stock hits 52-week high at 92.0 USD

Proto Labs Inc. (PRLB) shares have reached a new 52-week high of $92.00, driven by an impressive 90% total return over the past year and nearly 79% year-to-date. This growth follows strong Q2 results, exceeding analyst expectations with record revenue and adjusted earnings, and …

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright has lowered its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18, while maintaining a Buy rating, following the company's Q2 2026 financial results and an expanded Phase 2b trial for its lead asset, SL-325. Despite the price target cut, the …

Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17

Needham has reiterated its Buy rating for Shattuck Labs (STTK.US) and maintained its price target at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.

ABSI Archives

This page provides news and articles related to Absci Corp (ABSI), a company specializing in generative AI for drug discovery. It highlights Absci's stock data and features an article discussing a major IPO targeting the healthcare AI sector, which could influence companies like Absci. …

BTIG Research Reiterates Buy Rating for Absci (NASDAQ:ABSI)

BTIG Research has reaffirmed its "Buy" rating for Absci (NASDAQ:ABSI) and set a $13.00 price target, suggesting a potential upside of over 38%. This aligns with the overall positive sentiment from analysts, with eight recommending a "Buy" and one a "Sell," leading to a …

TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating

TD Cowen has reiterated its Buy rating for Absci Corp (ABSI.US). The firm did not specify any changes to its price target in this update.

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received a "Moderate Buy" consensus rating from analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $36.57, though recent targets vary from $21 to $40. The company reported a …

Tema ETFs LLC Has $52.71 Million Stake in Planet Labs PBC $PL

Several Insiders Invested In Shattuck Labs Flagging Positive News

Several insiders at Shattuck Labs (NASDAQ:STTK) have recently bought shares, with one independent director purchasing US$250k worth. While this buying activity occurred at a price below current market value, it suggests insiders view the company's prospects positively. Despite a recent loss, the substantial insider …

Alfabs Australia (ASX:AAL) Mining Services Growth Story Draws Value Investor Attention

Australian Clinical Labs (ASX:ACL) Value Case Builds as Healthcare Stock Reprices

Form 8K Shattuck Labs Inc For: 11 August By Investing.com

This article announces that Shattuck Labs Inc. filed a Form 8K on August 11, according to Investing.com. The brief news item includes the company's stock symbol STTK and its positive performance for the day. No further details about the content of the Form 8K …

MOBIX LABS, INC. (MOBX) Earnings Forecast: Future EPS & Revenue Growth Estimates

GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway

GeoVax Labs Inc. is preparing to initiate a pivotal phase 3 trial for its GEO-MVA mpox and smallpox vaccine candidate by the end of 2024, following an expedited regulatory pathway granted by the European Medicines Agency (EMA). The EMA waived phase 1 and 2 …

Jyothy Labs Q1 Results: Net Profit Slumps 51% As Margin Shrinks, Revenue Up 3% YoY; Stock Falls 4%

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

Lyka Labs standalone profit surges 159% in Q1FY27 on export strength

VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for VivoSim Labs Ord Shs (VIVS), detailing its current stock performance, market capitalization, and P/E ratio. It also lists peer comparisons with other biotechnology and medical research companies, indicating the number of ratings and analysts for each. The …

Why is Absci stock tumbling today?

Absci Corp (ABSI) stock tumbled 16.6% in after-hours trading after the company reported second-quarter 2026 financial results that significantly missed revenue and earnings expectations. Q2 revenue was $300,000, half of the previous year's $600,000 and well below the $1.01 million consensus estimate, while the …

Absci Q2 Loss Narrows, Revenue Declines

Absci reported a narrower Q2 net loss of $25.2 million, or $0.23 per share, compared to $27.9 million, or $0.26 per share, in the prior year. Revenue for the quarter declined to $0.4 million from $1.9 million year-over-year. The company's cash and cash equivalents …

Absci Corp 2026: Revenue $318K, EPS ($0.21) — 10-Q Summary

Absci Corp (ABSI) reported its Q2 2026 results, showing partner program revenue of $318K, a net loss of ($33.21M), and a diluted loss per share of ($0.21). The decline in revenue is attributed to milestone timing, while the company continues to invest in its …

Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis

Absci Corporation Q2 2026 Earnings Call Summary

Absci anticipates ABS-201 interim proof of concept data in 2H 2026, while guiding cash runway into 2H 2028

Earnings Call Insights: Absci (ABSI) Q2 2026 MANAGEMENT VIEW * CEO Sean McClain said the company released “positive interim Phase I data” from the HEADLINE trial, adding “the data suggests the study drug was well tolerated with favorable safety and tolerability” and that “ABS-201's …

Absci (NASDAQ:ABSI) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Absci (NASDAQ:ABSI) reported its quarterly earnings, missing analyst expectations with a loss of $0.21 per share against a consensus of $0.19, and revenue of $0.32 million, significantly below the $0.89 million forecast. Despite the financial miss, the company highlighted promising interim Phase 1 results …

Absci Releases Q2 2026 Financial Results

Absci Corporation (ABSI) announced its Q2 2026 financial results, reporting a wider-than-expected loss of $0.21 per share against an estimated $0.20 loss. Revenue reached $318,000, significantly missing the $931,670 estimate and marking a 46.0% year-over-year decline. The company posted a net loss of $33.2 …

Proto Labs (PRLB) Is Up 11.7% After Raising 2026 Revenue Guidance And Highlighting Rising Customer Spend

In late July 2026, Proto Labs, Inc. reported past second-quarter results showing sales of US$149.34 million and net income of US$9.15 million, alongside raising its full-year 2026 revenue growth guidance to 8%–10% and issuing new third-quarter earnings guidance. Management highlighted a 17% year-over-year increase …

Absci GAAP EPS of -$0.21 misses by $0.01, revenue of $0.3M misses by $0.63M

* Absci press release [https://seekingalpha.com/pr/20615676-absci-reports-business-updates-and-second-quarter-2026-financial-and-operating-results] (ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.21 misses by $0.01. * Revenue of $0.3M (-50.0% Y/Y) misses by $0.63M. * Cash, cash equivalents, and marketable securities as of June 30, 2026 were $201.1 million, compared to $125.7 million as …

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

Absci Corporation (NASDAQ: ABSI) boosts cash to $201M while net loss deepens

Absci Corporation reported a widening net loss of $33.2 million for Q2 2026 and $62.8 million for the first half of 2026, primarily due to increased R&D spending on its lead antibody ABS-201. Despite declining partner program revenue, the company significantly strengthened its balance …

Shattuck Labs, Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 108% Upside

Analysts have lowered the average 12-month price target for Shattuck Labs, Inc. (STTK) stock from $15 to $14.86, implying a potential upside of 108% based on the August 10 closing price. Despite the reduction, the consensus rating from 9 covering analysts remains a "Buy," …

STTK Maintained by HC Wainwright & Co. -- Price Target Lowered to $14

HC Wainwright & Co. has maintained a 'Buy' rating for Shattuck Labs (STTK) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook due to the company's significant overvaluation, low profitability, and mixed insider sentiment. Despite developing innovative therapies, the stock …

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

HC Wainwright has reduced its price target for Shattuck Labs (NASDAQ:STTK) to $14.00 from $18.00, while maintaining a "buy" rating, indicating a potential upside of approximately 94%. Despite the lowered target, analysts collectively give the company a "Moderate Buy" rating with an average target …

Astera Labs Posted 104% Revenue Growth in Q2. Why Is ALAB Down From Its Highs?

Astera Labs (ALAB) reported strong Q2 revenue growth of 104% year-over-year, beating analyst expectations, and provided optimistic Q3 guidance. Despite this strong performance and raised analyst targets, the stock is down from its highs, trading at a high valuation multiple. The company's growth drivers …

Shattuck Labs 2Q Loss/Shr 12c >STTK

Shattuck Labs (STTK) reported a second-quarter loss per share of 12 cents. Further details regarding their financial performance were not provided in this brief announcement.

Astera Labs Inc (Derivatives): Latest News, Social Media Updates and Insights

This article provides the latest news and social media updates for Astera Labs Inc (Derivatives). It highlights that 12 Nasdaq 100 stocks, including Sandisk, have more than doubled in 2026, with none of them being part of the "Magnificent Seven" group. The article also …